Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Clairvoyant Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The clinical trial, titled CLA-PSY-201, will evaluate the safety and efficacy of a 25 mg synthetic psilocybin capsule versus placebo, with Motivational Enhancement Therapy (MET).
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
October 18, 2022
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Clairvoyant Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
